TGTX vs. LLY
TGTX (TG Therapeutics, Inc.) and LLY (Eli Lilly and Company) are both stocks. Both are in the Healthcare sector — TGTX in Biotechnology, LLY in Drug Manufacturers - General. Over the past 10 years, TGTX returned 21.61%/yr vs 33.45%/yr for LLY. At a 0.18 correlation, their price movements are largely independent.
Performance
TGTX vs. LLY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TGTX achieves a 66.12% return, which is significantly higher than LLY's 5.78% return. Over the past 10 years, TGTX has underperformed LLY with an annualized return of 21.61%, while LLY has yielded a comparatively higher 33.45% annualized return.
TGTX
- 1D
- 3.06%
- 1M
- 16.11%
- YTD
- 66.12%
- 6M
- 57.96%
- 1Y
- 32.51%
- 3Y*
- 21.69%
- 5Y*
- 5.57%
- 10Y*
- 21.61%
LLY
- 1D
- -2.41%
- 1M
- 11.74%
- YTD
- 5.78%
- 6M
- 10.64%
- 1Y
- 40.51%
- 3Y*
- 37.45%
- 5Y*
- 39.59%
- 10Y*
- 33.45%
TGTX vs. LLY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
TGTX TG Therapeutics, Inc. | 66.12% | -0.96% | 76.23% | 44.38% | -37.74% | -63.48% | 368.65% | 170.73% | -50.00% | 76.34% |
LLY Eli Lilly and Company | 5.78% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
Correlation
The correlation between TGTX and LLY is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.17 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since May 3, 2010 | 0.18 |
Fundamentals
TGTX:
$7.93B
LLY:
$1.02T
TGTX:
$2.87
LLY:
$28.14
TGTX:
17.23
LLY:
40.26
TGTX:
0.03
LLY:
0.81
TGTX:
11.37
LLY:
14.08
TGTX:
13.59
LLY:
32.54
TGTX:
$700.35M
LLY:
$72.25B
TGTX:
$581.54M
LLY:
$59.75B
TGTX:
$156.88M
LLY:
$32.97B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TGTX vs. LLY — Risk / Return Rank
TGTX
LLY
TGTX vs. LLY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for TG Therapeutics, Inc. (TGTX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TGTX | LLY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.38 | ||
| Sortino ratioReturn per unit of downside risk | -0.33 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.22 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 1.00 | 1.72 | -0.72 |
| Martin ratioReturn relative to average drawdown | 1.81 | 4.28 | -2.47 |
Loading charts...
Drawdowns
TGTX vs. LLY - Drawdown Comparison
The maximum TGTX drawdown since its inception was -99.52%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for TGTX and LLY.
Loading charts...
Drawdown Indicators
| TGTX | LLY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.52% | -68.24% | -31.28% |
Max Drawdown (1Y)Largest decline over 1 year | -32.66% | -23.64% | -9.02% |
Max Drawdown (3Y)Largest decline over 3 years | -75.42% | -34.48% | -40.94% |
Max Drawdown (5Y)Largest decline over 5 years | -90.75% | -34.48% | -56.27% |
Max Drawdown (10Y)Largest decline over 10 years | -93.19% | -34.48% | -58.71% |
Current DrawdownCurrent decline from peak | -78.79% | -2.41% | -76.38% |
Average DrawdownAverage peak-to-trough decline | -91.43% | -19.21% | -72.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.04% | 9.49% | +8.55% |
Volatility
TGTX vs. LLY - Volatility Comparison
TG Therapeutics, Inc. (TGTX) has a higher volatility of 15.65% compared to Eli Lilly and Company (LLY) at 9.27%. This indicates that TGTX's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TGTX | LLY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.65% | 9.27% | +6.38% |
Volatility (6M)Calculated over the trailing 6-month period | 34.28% | 27.16% | +7.12% |
Volatility (1Y)Calculated over the trailing 1-year period | 47.22% | 38.01% | +9.21% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 87.77% | 32.46% | +55.31% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 86.88% | 30.19% | +56.69% |
Dividends
TGTX vs. LLY - Dividend Comparison
TGTX has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.57%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LLY Eli Lilly and Company | 0.57% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
TGTX TG Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
TGTX vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between TG Therapeutics, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TGTX vs. LLY - Profitability Comparison
TGTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported a gross profit of 171.41M and revenue of 204.92M. Therefore, the gross margin over that period was 83.7%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported a gross profit of 15.64B and revenue of 19.80B. Therefore, the gross margin over that period was 79.0%.
TGTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported an operating income of 34.80M and revenue of 204.92M, resulting in an operating margin of 17.0%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported an operating income of 9.19B and revenue of 19.80B, resulting in an operating margin of 46.4%.
TGTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported a net income of 19.78M and revenue of 204.92M, resulting in a net margin of 9.7%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported a net income of 7.40B and revenue of 19.80B, resulting in a net margin of 37.4%.
Frequently Asked Questions
TGTX and LLY have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TGTX has higher volatility (15.65%) compared to LLY (9.27%). In terms of maximum drawdown, TGTX dropped -99.52% vs LLY's -68.24%.
LLY currently has the higher Sharpe Ratio (1.07 vs 0.69), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TGTX and LLY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer